Scarica l'app Stockscreener
12.98
0.85%
0.11
Pre-mercato:
12.94
-0.04
-0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SDGR Giù?
Forum
Previsione
Precedente Chiudi:
$12.87
Aprire:
$12.18
Volume 24 ore:
2.56M
Relative Volume:
1.77
Capitalizzazione di mercato:
$969.87M
Reddito:
$255.87M
Utile/perdita netta:
$-103.27M
Rapporto P/E:
-9.1998
EPS:
-1.4109
Flusso di cassa netto:
$12.46M
1 W Prestazione:
+10.37%
1M Prestazione:
+12.67%
6M Prestazione:
-30.40%
1 anno Prestazione:
-44.91%
Intervallo 1D:
$11.56
$12.98
Intervallo di 1 settimana:
$11.56
$13.25
Portata 52W:
$10.95
$27.63
Schrodinger Inc Stock (SDGR) Company Profile
Nome
Schrodinger Inc
Settore
Industria
Telefono
503-299-1150
Indirizzo
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, BTSG, TEM, HQY, DOCS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
12.98 | 961.66M | 255.87M | -103.27M | 12.46M | -1.4109 |
VEEV
Veeva Systems Inc
|
167.35 | 27.94B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
52.74 | 9.98B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
53.50 | 9.70B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
83.25 | 6.98B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
25.69 | 4.76B | 637.78M | 239.40M | 307.21M | 1.1909 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Neutral |
| 2025-08-15 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-14 | Iniziato | Barclays | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-07-02 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | Ripresa | Piper Sandler | Overweight |
| 2022-12-19 | Iniziato | Goldman | Neutral |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-13 | Iniziato | Berenberg | Buy |
| 2021-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | Iniziato | Craig Hallum | Buy |
| 2020-11-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-10-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-02 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-02 | Iniziato | Jefferies | Hold |
| 2020-03-02 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Schrodinger Inc Borsa (SDGR) Ultime notizie
A Look At Schrödinger (NasdaqGS:SDGR) Valuation After Q1 Earnings And Hosted AI Software Push - Yahoo Finance
Schrödinger, Inc. (NASDAQ:SDGR) Q1 2026 Earnings Call Transcript - Insider Monkey
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating - Moomoo
Schrödinger Reports First Quarter 2026 Financial Results - BioSpace
Schrödinger, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SDGR) 2026-05-06 - Seeking Alpha
Schrödinger Q1 2026 slides: AI platform advances amid transition By Investing.com - Investing.com South Africa
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates - MSN
Schrodinger Q1 Earnings Call Highlights - Yahoo Finance
TD Cowen Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Schrödinger outlines $218M-$228M 2026 ACV outlook with focus on hosted transition and Bunsen early access release - MSN
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Schrödinger Earnings Call: Growth Now, Profits Later - TipRanks
Schrödinger Inc (NASDAQ:SDGR) Q1 2026 Earnings: Revenue Beat Fails to Offset Loss Miss, Stock Slides - ChartMill
Schrödinger (SDGR) Q1 2026 Earnings Transcript - AOL.com
Schrödinger Q1 2026 slides: AI platform advances amid transition - Investing.com
Earnings call transcript: Schrödinger misses EPS but beats revenue in Q1 2026 - Investing.com
Earnings Flash (SDGR) Schrodinger, Inc. Reports Q1 Revenue $58.6M, vs. FactSet Est of $47.6M - marketscreener.com
Q1 2026 Schrodinger Inc Earnings Call Transcript - GuruFocus
Schrödinger tees up AI drug-discovery tool as Ajax sale hits $2.3B - Stock Titan
Schrödinger (NASDAQ: SDGR) Q1 2026 revenue, loss and cash position - Stock Titan
Schrödinger, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Schrödinger (NASDAQ: SDGR) posts Q1 2026 $58.6M revenue, keeps outlook - Stock Titan
Can Schrödinger’s (SDGR) AI-Hosted Push Recast Its Investment Story Beyond Drug Discovery Hype? - simplywall.st
MSN Money - MSN
Here’s What the Street Thinks About Schrödinger (SDGR) - Insider Monkey
Schrödinger to Participate in Upcoming Investor Conferences - PharmiWeb.com
Liquidity Mapping Around (SDGR) Price Events - Stock Traders Daily
Schrödinger to Participate in Upcoming May 2026 Investor Conferences - BioSpace
Schrödinger will webcast two healthcare conference talks in May - Stock Titan
Insider sales reported for SDGR (NASDAQ: SDGR) including 752/775/608 shares - Stock Titan
SDGR Stock Price, Quote & Chart | SCHRODINGER INC (NASDAQ:SDGR) - ChartMill
3.19M-share disclosure by Schrodinger (NASDAQ: SDGR) shows a 4.9% stake - Stock Titan
Earnings Preview: Schrodinger to Report Financial Results Post-market on May 05 - Moomoo
Vanguard Portfolio Management (SDGR) holds 3.91M shares, 6.04% stake - Stock Titan
AI in Predictive Toxicology Research Report 2026 Featuring Certara, Schrodinger, Instem, Simulations Plus, Lhasa, ChemaxonGlobal Forecast to 2030 and 2035 - Yahoo Finance
Schrodinger (SDGR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Schrödinger Appoints Geoffrey Porges as Chief Financial Officer - Quantisnow
Form DEFA14A Schrodinger, Inc. - StreetInsider
[ARS] Schrodinger, Inc. SEC Filing - Stock Titan
Schrödinger (NASDAQ: SDGR) seeks approval for 3M-share equity plan increase - Stock Titan
EDGAR Filing Documents for 0001490978-26-000028 - SEC.gov
Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight - GlobeNewswire Inc.
Schrödinger updates 2025 software growth guidance to 8%-13% amid pharma scale-up delays and operational efficiency focus - MSN
Schrodinger downgraded at Citi after clinical program exit - MSN
Why (SDGR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
SDGR (Schrodinger Inc.) Q4 2025 EPS far outpaces consensus estimates, shares climb 2.32 percent.Fast Rising Picks - Xã Thanh Hà
Schrodinger Inc (SDGR) Shares Fall 4.1% -- What GF Score of 69 T - GuruFocus
Schrodinger: AI Threat Is Looming Large (Rating Downgrade) - Seeking Alpha
Schrodinger, Inc. (NASDAQ:SDGR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Schrodinger Inc Azioni (SDGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):